Literature DB >> 31309572

Characterization of Severe Adverse Drug Reactions at a Free-Standing Children's Hospital.

Diana Yu1, Justin Sheets2, Sarah Suppes2, Jennifer Goldman2.   

Abstract

We performed a retrospective chart review on severe adverse drug reactions (ADRs) detected by a pharmacovigilance program at a free-standing pediatric hospital from January 2011 through September 2014. The pharmacist-led program identifies ADRs using electronic medical record triggers. A systematic approach was used to classify ADR type and severity and assure accurate documentation. Data collection included demographics, implicated medication, type of ADR, Naranjo probability scale, ADR-associated International Classification of Diseases, 9th Revision E codes, 30-day mortality, and health care visit cost. One hundred sixty-six severe pediatric ADRs were included, occurring in 163 unique patients. Severe ADRs were commonly associated with antimicrobials (48%), antineoplastics (10%), and antiepileptics (10%). The majority of ADRs were classified by the Naranjo probability scale as probable (59%). One hundred fifty-four patients were admitted to the hospital, with a median length of stay of 3 days; 22 of these patients required admission to the pediatric intensive care unit for a median of 3 days. The median estimated health care cost associated with severe ADRs was $4055.52. No deaths occurred. Nearly 40% of severe ADRs would have gone unidentified using ADR-associated International Classification of Diseases, 9th Revision E codes alone. The impact of pediatric ADRs on the health care system is underestimated. Strategies such as active pharmacovigilance programs enhance the identification, characterization, and documentation of these otherwise unrecognized ADRs.
© 2019, The American College of Clinical Pharmacology.

Entities:  

Keywords:  adverse drug reactions; pediatrics; pharmacovigilance

Year:  2019        PMID: 31309572     DOI: 10.1002/jcph.1494

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1. 

Authors:  Pauline Rault; Amélie Duhamel; Dana Necsoiu; Isabelle Desjardins; Denis Lebel; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2020-02-01

2.  Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children's hospital.

Authors:  Madhavi Murali; Sarah L Suppes; Keith Feldman; Jennifer L Goldman
Journal:  PLoS One       Date:  2021-01-13       Impact factor: 3.240

3.  Risks and mitigation strategies to prevent etoposide infusion-related reactions in children.

Authors:  Emma M Tillman; Sarah L Suppes; Nicholas Miles; Ashley M Duty; Kelsey L Kelley; Jennifer L Goldman
Journal:  Pharmacotherapy       Date:  2021-06-29       Impact factor: 4.705

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.